Holen Sie sich die Stockscreener-App
45.45
0.61%
-0.28
Handel nachbörslich:
45.46
0.010
+0.02%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt BMY?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$45.73
Offen:
$45.2
24-Stunden-Volumen:
17.89M
Relative Volume:
1.35
Marktkapitalisierung:
$92.51B
Einnahmen:
$47.70B
Nettoeinkommen (Verlust:
$5.07B
KGV:
18.34
EPS:
2.4784
Netto-Cashflow:
$14.58B
1W Leistung:
+3.01%
1M Leistung:
-4.32%
6M Leistung:
-21.39%
1J Leistung:
-16.14%
1-Tages-Spanne:
$44.66
$46.17
1-Wochen-Bereich:
$43.78
$48.58
52-Wochen-Spanne:
$42.96
$63.33
Bristol Myers Squibb Co Stock (BMY) Company Profile
Firmenname
Bristol Myers Squibb Co
Sektor
Telefon
(609) 252-4621
Adresse
ROUTE 206 AND PROVINCE LINE ROAD, PRINCETON, NY
Vergleichen Sie BMY mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BMY
Bristol Myers Squibb Co
|
45.45 | 93.08B | 47.70B | 5.07B | 14.58B | 2.4784 |
|
LLY
Lilly Eli Co
|
839.87 | 734.96B | 53.26B | 13.80B | -50.20M | 15.08 |
|
JNJ
Johnson Johnson
|
188.64 | 447.90B | 90.62B | 22.66B | 18.18B | 9.35 |
|
ABBV
Abbvie Inc
|
233.91 | 417.90B | 58.33B | 3.73B | 18.24B | 2.1013 |
|
NVS
Novartis Ag Adr
|
132.39 | 253.54B | 53.40B | 13.68B | 16.89B | 6.8864 |
|
MRK
Merck Co Inc
|
89.19 | 223.58B | 63.43B | 16.42B | 14.72B | 6.4861 |
Bristol Myers Squibb Co Stock (BMY) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-08-05 | Herabstufung | Daiwa Securities | Outperform → Neutral |
| 2025-04-22 | Eingeleitet | Cantor Fitzgerald | Neutral |
| 2025-04-22 | Eingeleitet | Piper Sandler | Overweight |
| 2024-12-16 | Hochstufung | Jefferies | Hold → Buy |
| 2024-12-10 | Fortgesetzt | BofA Securities | Neutral |
| 2024-11-15 | Eingeleitet | Wolfe Research | Peer Perform |
| 2024-11-13 | Hochstufung | Daiwa Securities | Neutral → Outperform |
| 2024-11-12 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-10-25 | Herabstufung | Citigroup | Buy → Neutral |
| 2024-10-17 | Eingeleitet | Bernstein | Mkt Perform |
| 2024-07-29 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2024-03-11 | Herabstufung | Societe Generale | Buy → Hold |
| 2024-02-06 | Herabstufung | Redburn Atlantic | Buy → Neutral |
| 2024-01-03 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-11-15 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2023-11-09 | Eingeleitet | Deutsche Bank | Hold |
| 2023-11-02 | Herabstufung | Daiwa Securities | Outperform → Neutral |
| 2023-10-27 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2023-10-27 | Hochstufung | HSBC Securities | Reduce → Hold |
| 2023-10-27 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2023-10-20 | Fortgesetzt | UBS | Neutral |
| 2023-07-14 | Eingeleitet | HSBC Securities | Reduce |
| 2023-07-10 | Eingeleitet | SVB Securities | Market Perform |
| 2023-06-28 | Eingeleitet | Daiwa Securities | Outperform |
| 2023-03-06 | Eingeleitet | Jefferies | Hold |
| 2023-01-17 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2022-11-18 | Eingeleitet | Credit Suisse | Neutral |
| 2022-10-10 | Herabstufung | Guggenheim | Buy → Neutral |
| 2022-09-14 | Herabstufung | Berenberg | Buy → Hold |
| 2022-06-03 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2022-04-06 | Fortgesetzt | Morgan Stanley | Underweight |
| 2021-12-17 | Eingeleitet | Goldman | Buy |
| 2021-12-09 | Fortgesetzt | Wells Fargo | Equal Weight |
| 2021-11-19 | Eingeleitet | BMO Capital Markets | Outperform |
| 2021-11-01 | Herabstufung | Argus | Buy → Hold |
| 2021-07-27 | Fortgesetzt | Truist | Buy |
| 2021-04-30 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-04-13 | Hochstufung | Truist | Hold → Buy |
| 2020-11-16 | Hochstufung | Societe Generale | Hold → Buy |
| 2020-11-10 | Fortgesetzt | Bernstein | Mkt Perform |
| 2020-11-06 | Herabstufung | Gabelli & Co | Buy → Hold |
| 2020-10-19 | Hochstufung | Guggenheim | Neutral → Buy |
| 2020-09-29 | Eingeleitet | Berenberg | Buy |
| 2020-07-28 | Eingeleitet | Raymond James | Outperform |
| 2020-04-02 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2020-03-23 | Herabstufung | Societe Generale | Buy → Hold |
| 2020-02-27 | Eingeleitet | Barclays | Equal Weight |
| 2020-01-06 | Fortgesetzt | Citigroup | Buy |
| 2019-12-13 | Hochstufung | Argus | Hold → Buy |
| 2019-11-22 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2019-10-17 | Fortgesetzt | BofA/Merrill | Buy |
| 2019-08-14 | Hochstufung | Atlantic Equities | Neutral → Overweight |
| 2019-05-28 | Eingeleitet | Goldman | Buy |
| 2019-05-20 | Herabstufung | Argus | Buy → Hold |
| 2019-05-03 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2019-05-03 | Fortgesetzt | JP Morgan | Overweight |
| 2019-01-15 | Hochstufung | Societe Generale | Sell → Buy |
| 2018-10-22 | Herabstufung | Citigroup | Buy → Neutral |
Alle ansehen
Bristol Myers Squibb Co Aktie (BMY) Neueste Nachrichten
Bristol Myers Squibb Stock Hits Day High with Strong Intraday Performance - Markets Mojo
How Bristol Myers Squibb Company (BRM) stock performs during market turbulenceRisk Management & Fast Moving Market Watchlists - newser.com
Bristol-Myers Squibb, Takeda, Astex Join AI Consortium to Train OpenFold3 for Accelerated Drug Discovery - Insider Monkey
PTAB Condemns Bristol-Myers' 'Whac-A-Mole Strategy' - Law360
11 Best Affordable Dividend Stocks to Buy Now - Insider Monkey
Bristol Myers Squibb Co. stock underperforms Thursday when compared to competitors - MarketWatch
These 3 Pharma Stocks Are Rallying – And Still Trade Absurdly Cheap - Benzinga
Bristol-Myers retirees win round in lawsuit over $2B Athene annuity deal - InsuranceNewsNet
Bristol Myers Alzheimer's Drug Earns FDA Fast Track - Yahoo
Bristol-Myers Squibb Co (BMY) Stock Price, Trades & News - GuruFocus
Bristol-Myers Squibb (BMY) Reports Strong Multiple Myeloma Data - Insider Monkey
Bristol-Myers Squibb Company (BMY) Begins Selling Its Psoriasis Medication Sotyktu Directly to Cash-Paying U.S. Customers - Insider Monkey
Judge Lets Core Claims Proceed in PRT Case Against Bristol-Myers Squibb - plansponsor
FDA grants fast track designation for Alzheimer’s drug BMS-986446 - Investing.com India
Major Alzheimer's Breakthrough: BMS-Prothena Drug Gets FDA Fast Track for Targeting Tau Protein - Stock Titan
Bristol Myers Squibb Co. Experiences Revision in Stock Evaluation Amid Market Dynamics - Markets Mojo
Ex-Dividend Reminder: Quest Diagnostics, Bristol Myers Squibb and Globe Life - Nasdaq
Bristol Myers (BMY) Receives Fast Track Status for Alzheimer's T - GuruFocus
Wall Street's Most Accurate Analysts Weigh In On 3 Health Care Stocks With Over 4% Dividend Yields - Benzinga
FDA grants fast track designation for Bristol Myers Squibb’s Alzheimer’s drug - Investing.com Nigeria
Bristol Myers Squibb (BMY) Joins Consortium for AI Drug Discover - GuruFocus
BMYBristol-Myers Squibb Co Latest Stock News & Market Updates - Stock Titan
Big pharma firms announce direct-to-consumer sales and price cuts in U.S. - Reuters
Bristol Myers, Takeda to pool data for AI-based drug discovery By Reuters - Investing.com
Bristol Myers, Takeda to pool data for AI-based drug discovery - Yahoo
Judge denies motions by Bristol-Myers Squibb, State Street IM to dismiss PRT lawsuit - Pensions & Investments
Bernstein Maintains a Hold on Bristol-Myers Squibb Company (BMY) - Insider Monkey
Bristol Myers Squibb call volume above normal and directionally bullish - TipRanks
Multiple Modalities in the Oncology Market Size, Regional Growth and Trends - GlobeNewswire Inc.
Bristol-Myers Retirees’ Pension De-Risking Suit Moves Forward - Bloomberg Law News
Bristol Myers Squibb Company $BMY Position Cut by Capital Investment Advisors LLC - MarketBeat
Is this a good reentry point in Bristol Myers Squibb Company Equity Right2025 Trading Recap & AI Driven Price Predictions - newser.com
Bristol-Myers Squibb Company (BMY) to Capitalize on Cell Therapy Edge to Pursue CAR-T Treatment Opportunities - Insider Monkey
Will Bristol Myers Squibb Company stock boost dividends further2025 Technical Overview & Accurate Entry and Exit Point Alerts - newser.com
AbbVie to launch ovarian cancer drug in UK at US price - Reuters
How Bristol-Myers Squibb Company (BMY) Delivers Strong Yields Even in Tough Markets - Insider Monkey
JLL: Bristol Myers Squibb eyes sale, partial leaseback of 1.2 million sq. ft. Summit campus - RE-NJ
Using AI based signals to follow Bristol Myers Squibb CompanyJuly 2025 Earnings & Risk Adjusted Buy and Sell Alerts - newser.com
Bristol-Myers Squibb Company (BMY) Stock Analysis: 20% Upside Potential Amid Strong Dividend Yield - DirectorsTalk Interviews
Bristol Myers Squibb Company (BMY) Is a Trending Stock: Facts to Know Before Betting on It - sharewise.com
Fort Washington Investment Advisors Inc. OH Acquires 7,095 Shares of Bristol Myers Squibb Company $BMY - MarketBeat
KG&L Capital Management LLC Buys 39,136 Shares of Bristol Myers Squibb Company $BMY - MarketBeat
Is Bristol Myers Squibb Company Celegne Contingent stock inflation resilientWeekly Trend Recap & Verified Short-Term Trading Plans - newser.com
Why Bristol-Myers Squibb (BMY) Deserves a Spot in Passive Income Portfolios - Insider Monkey
Perigon Wealth Management LLC Has $2.48 Million Holdings in Bristol Myers Squibb Company $BMY - MarketBeat
Bristol Myers Squibb Company $BMY Position Trimmed by TD Private Client Wealth LLC - MarketBeat
Trump's Drug Tariffs 'A Meaningful Commercial Hit' For Americans, Says AnalystEli Lilly (NYSE:LLY), Bristol-Myers Squibb (NYSE:BMY) - Benzinga
Bristol Myers Squibb discovers new TLR7 agonists - BioWorld MedTech
Can swing trading help recover from Bristol Myers Squibb Company losses2025 Historical Comparison & AI Powered Buy and Sell Recommendations - newser.com
BMS adds discounted psoriasis drug to its DTC channel - pharmaphorum
Meyer Handelman Co. Has $24.44 Million Stock Position in Bristol Myers Squibb Company $BMY - MarketBeat
Finanzdaten der Bristol Myers Squibb Co-Aktie (BMY)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.52%
0.36%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):